Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:41:58.133Z.
Consensus retrieved: 2026-10-06T11:44:26.581Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:41:58.133Z.
Quote observation: 2026-10-06T14:40:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e4786eb28a8a31d15cdec8f673983fbe0ec0b626c310469f8e20e074e44c13d
Forward PE Ratio (N/A) = Dated Quote Price ($26.34) / Consensus Forward EPS ($-15.07)
FORWARD PE RATIO
N/A
Faeth Therapeutics, Inc.
Market Cap
$678.96M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | $678.96M | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $690.35M | N/A |
| Annexon, Inc. (ANNX)vs › | $666.02M | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $663.69M | N/A |
| Helus Pharma Inc. (HELP)vs › | $655.17M | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $703.70M | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $650.20M | N/A |
| OmniAb, Inc. (OABI)vs › | $647.30M | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $712.45M | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $635.62M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $26.34, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-15.07 | $-16.73 – $-13.19 | 6 | n/m |
| 2027-12-31 | $-3.28 | $-4.82 – $-2.51 | 6 | n/m |
| 2028-12-31 | $-3.82 | $-6.09 – $-2.58 | 9 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
